Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04473651 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability of Lu AG06479 in Healthy Young Men

A Phase 1 study, sponsored by H. Lundbeck A/S.

Terminated
Registry status
Phase 1
Development phase
46
Enrollment target

NCT04473651 is a Phase 1 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 46 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04473651, a Phase 1 study, was terminated before completion, sponsored by H. Lundbeck A/S.

TERMINATED
Registry status
Phase 1
Development phase
46 participants
Enrollment target

Study Summary

The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.

Interventions

  • DRUG Placebos
  • DRUG Lu AG06479

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2020-07-09
Est. Completion 2021-11-10
Phase Phase 1

Sponsor

H. Lundbeck A/S

72 total trials

What the Registry Record Tells You About NCT04473651

The ClinicalTrials.gov registry entry for NCT04473651 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.

NCT04473651 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04473651 about?

NCT04473651 is a clinical study titled "Safety and Tolerability of Lu AG06479 in Healthy Young Men". The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.

What is the current status of trial NCT04473651?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2020-07-09. Estimated completion is 2021-11-10.

What interventions are being tested in trial NCT04473651?

The interventions under investigation include: Placebos (DRUG), Lu AG06479 (DRUG).

Who is sponsoring clinical trial NCT04473651?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.